menu search

CNTX / Context Therapeutics finds lead clinical development candidate for cancer treatment in CTIM-76

Context Therapeutics finds lead clinical development candidate for cancer treatment in CTIM-76
Context Therapeutics (NASDAQ:CNTX) Inc has designated CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers, the company announced.  The CLDN6 gene is differentially expressed on cancer cells but has no or very low expression in normal, healthy tissue. Read More
Posted: Nov 29 2022, 10:52
Author Name: Proactive Investors
Views: 103185

CNTX News  

Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatment

By Proactive Investors
October 31, 2023

Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatment

Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6 more_horizontal

Context Therapeutic says it has enough cash to fund operation into late 2024

By Proactive Investors
August 10, 2023

Context Therapeutic says it has enough cash to fund operation into late 2024

Context Therapeutics (NASDAQ:CNTX) Inc. has announced its financial results for the second quarter ended June 30, 2023, highlighting that it has suffi more_horizontal

Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024

By Proactive Investors
May 11, 2023

Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024

Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's c more_horizontal

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinar

By Proactive Investors
April 16, 2023

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinar

Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, more_horizontal

Context Therapeutics announces pipeline update with FY 2022 financial results

By Proactive Investors
March 23, 2023

Context Therapeutics announces pipeline update with FY 2022 financial results

Context Therapeutics (NASDAQ:CNTX) has announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway more_horizontal

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting

By Proactive Investors
March 15, 2023

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting

Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, more_horizontal

Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancer

By Proactive Investors
February 6, 2023

Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancer

Context Therapeutics (NASDAQ:CNTX) Inc has highlighted encouraging clinical responses from its Phase 2 OATH clinical trial evaluating ONA-XR to treat more_horizontal

Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancers

By Proactive Investors
January 9, 2023

Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancers

Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech more_horizontal


Search within

Pages Search Results: